CureVac
mRNA medical technology development
- B2B
About CureVac
Global biopharmaceutical company specializing in mRNA technology to develop vaccines, cancer therapies, and rare disease treatments by instructing the body to produce proteins
Key facts
- Industry
- Biotechnology Research
- Company size
- 251–1,000 employees
- Headquarters
- Tübingen, Baden-Württemberg, Germany
- Founded
- 2000
- Revenue
- €535MFY2024, publicly reported
- Website
- curevac.com
- linkedin.com/company/curevac
CureVac in the news
- Morning Briefing: Biontech, Curevac – und die Bilanz des Staats als Unternehmer
The German government experienced a significant loss on its investment in CureVac, while BioNTech is scaling back operations, and the government is trying to block a Chinese acquisition of Zippel.
- Betriebsrat zu gescheiterten Verkaufsplänen: Für Curevac gibt es keine Hoffnung mehr
Curevac's planned sale fell through, leading to its definitive closure by the end of 2027.
- Biontech-Schließungen: Curevac-Kaufinteressenten erheben harte Vorwürfe
A US-led consortium interested in acquiring the former Curevac site accuses Biontech of not trying to save it.
- Licensable picture: Curevac in Tübingen
The image shows the CureVac site in Tübingen, which is part of the BioNTech Group.
- Palmer nennt BioNTech-Aus in Tübingen "erschreckend" - und bangt um Arbeitsplätze
BioNTech is closing three German production sites by 2028, including the former CureVac headquarters in Tübingen, due to decreased COVID-19 vaccine demand, impacting 1,800 jobs.
CureVac at a glance
CureVac is a B2B company in the Biotechnology Research industry, headquartered in Tübingen, Baden-Württemberg, Germany.
CureVac was founded in 2000.
CureVac has 251–1,000 employees.
CureVac's revenue is €535M (FY2024, publicly reported).
Selling to companies like CureVac?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies